The encouraging safety profile of tebotelimab may also facilitate immunotherapy opportunities in tumor types in which suboptimal exposures to anti-PD-1 or toxicity with CTLA-4 combinations have prevented clinical development. Here, CTLA4 is linked to neoplasm.